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ABSTRACT. The infectious bursal disease virus (IBDv) is widespread in poultry flocks all around the world. 
Various biotypes have emerged and because of that, adequate management practices and vaccination of chicks are of 
paramount importance for the protection against field strains. One day old Lohmann Brown chicks were vaccinated with 
intermediate vaccines and the recombinant VAXXITEK HVT-IBDv vaccine formulation, and challenged at 48 days of 
life with the very virulent IBDv (vvIBDv) strain CH/99. The best protection (100%) was achieved with the recombinant 
vaccine administered by the subcutaneous or intramuscular route at a day old, while intermediate and intermediate plus 
vaccines protected 80% of birds from clinical symptoms. The highest bursa body ratio (5.33, 3.50 and 4.12) was accom-
plished in non- vaccinated and non-challenged birds and birds vaccinated with the VAXXITEK HVT-IBDv vaccine. 
The recombinant VAXXITEK HVT-IBDv vaccine has provided protection for commercial chicks against challenge 
with the vvIBDv strain in this experiment. Under field conditions, additional vaccination is possibly needed with sup-
plementary application of live attenuated vaccines. However, the recombinant vector vaccines are providing significant 
aid against clinical signs and immunosupression caused by the vvIBDv.   
Keywords: poultry, IBDv, intermediate vaccines, recombinant vaccines, challenge
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INTRODUCTION
The infectious bursal disease virus (IBDv) causes health problems in poultry flocks all around the 
world. This virus is capable of spreading across a 
long distance and survives in a poultry farm environ-
ment, even if the farms were thoroughly cleaned and 
disinfected between production cycles. Once the farm 
is contaminated with the IBDv it is almost impossi-
ble to prevent the infection of chicks. Vaccination 
of chicks against IBDv is often inefficient due to 
the interference of maternally derived antibodies 
with vaccine viruses (Chettle et al., 1989). Studying 
molecular genetics of the virus and various vaccina-
tion approaches substantially contributed to under-
standing the biology of the IBDv and has improved 
control strategies (Müller et al., 2012).  
The IBDv is a double stranded RNA virus with 
a bisegmented genome and it belongs to the genus 
Avibirnavirus of the family Birnaviridae (Müller et 
al., 1979). The larger segment of the virus encodes 
the polyprotein, which is autocatalytically cleaved 
to VP2, VP3 and VP4 proteins, while a small over-
lapping open reading frame fragment encodes the 
protein VP5, which has a role in cell lysis and the 
apoptosis process. The smaller segment encodes an 
RNA dependent RNA polymerase (Mundt et al., 
1995). The most studied is the capsid protein VP2, 
since it is exposed at the surface of the virus and pos-
sesses conformational epitopes with different amino 
acid arrangements in various biotypes (Bayliss et al., 
1990). Therefore, the VP2 protein has become an 
important target for genetically engineered vaccines, 
some of which are based on the recombinant technol-
ogy (Darteil et al., 1995).
The turkey herpes virus (HVT) is an avirulent, cell 
associated virus and has been used for decades for 
the vaccination of chicks against Marek’s disease 
(MD).  As the Marek’s disease virus is ubiquitous, 
all commercial chicks have to be vaccinated in hatch-
eries subcutaneously at the first day of life or in ovo 
(Gimeno, 2008). Because of the cell associated nature 
of the HVT, it has become an attractive target for 
the development of vector vaccines. The basic con-
cept for the vaccination of chicks with rHVT-VP2 
depends on the expression of the VP2 at the surface 
of the cell which in turn induces immune respons-
es. The vector virus (VAXXITEK HVT-IBDv) was 
found in the feathers follicles, which means that the 
pathogenesis of the vaccine strains was well estab-
lished in the recombinant formulation (Gelb et al., 
2016). The partial aid, when it comes to the protec-
tion from MD, is also possible with some of the HVT 
recombinant vaccines (Aly et al., 2012). However, 
the results from research studies are different and the 
success of field vaccination depends on multiple fac-
tors such as management practices, and virulence and 
antigenicity of the field strains. 
Outbreaks of vvIBDv still occur in broiler and layer 
chicks in Serbia. Most commonly the vaccination 
with the intermediate plus vaccines takes place at 
approximately 10 days of age and second vaccine 
is given to chicks 7 to 10 days apart. In cases when 
for a longer period of time new outbreaks are not 
recorded, the intermediate vaccines are continuously 
used. Such control has shown some benefits but in 
farms with poor management practices it is still high-
ly risky to replace vaccination with the intermediate 
vaccines only. In such circumstances the option to 
vaccinate chicks as early as at day one or in ovo with 
the recombinant rHVT-VP2 seems to be promising. 
Hence, a challenge experiment was done to evaluate 
several vaccination protocols in order to gain experi-
ence with the rHVT-VP2 in Serbia. The goal was to 
perform an experimental infection of chicks vaccinat-
ed with the intermediate or intermediate plus vaccines 
per os and with the rHVT-VP2 vaccine subcutane-
ously or intramuscularly, in order to determine the 
level of protection against challenge with the vvIBDv 
strain. 
MATERIAL AND METHODS
General description
The following work was conducted at the Faculty 
of Veterinary Medicine in Belgrade. The facilities 
where the experiments were carried out were sep-
arated by concrete walls. The walls and concrete 
floors were easy to disinfect. The commercial feed 
produced by technology for Lohmann brown prove-
nience was prepared in a local feed factory according 
to HACCP quality assurance system and ISO 22000 
standards implemented.  Water was provided ad libi-
tum. The facility is the only establishment certified 
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for experiments involving poultry and as such it has 
permit issued by the Ministry of Agriculture of the 
Republic of Serbia, Veterinary Directorate (permit 
number 323-07-02263/2014-05/2).  The chicks from 
all the experimental groups were vaccinated in the 
hatchery against MD, infectious bronchitis (IB) and 
Newcastle disease (NDV). The type of MD vaccines 
used in this study is presented in experimental infec-
tion.  During the experiment, the complete vacci-
nation program against poultry diseases commonly 
applied in Serbia was also performed. The vaccines 
included those against Newcastle disease virus and 
infectious bronchitis virus i.e. Nobilis Ma5-Clone30, 
Nobilis ND clone30, IB Bioral H120 (MSD Animal 
Health, The Netherlands).
Vaccines against IBDv
Three types of commercial live IBD vaccines were 
used in the study: the intermediate (D78) and inter-
mediate plus vaccines (228E), (MSD Animal Health, 
The Netherlands) and the recombinant vector vaccine 
VAXXITEK HVT-IBDv (Merial-Sanofy, France). 
Challenge virus
For the challenge experiment, the local field vvIB-
Dv strain CH/99 was used. The CH/99 IBDv is the 
standard challenge strain used in Serbia. It was not 
titrated on chickens but it causes mortality of 50% 
layer chicks which are free of maternal antibodies. 
According to the amino acid sequences of the hyper-
variable domain of the VP2, this virus belongs to the 
very virulent biotype (GeneBank accession number 
KF439863), (Dobrosavljević et al., 2014).
Experimental infection
Sixty one-day old commercial Lohmann Brown 
chicks were held in isolation units and provided 
with feed and water ad libitum. Each vaccinated 
group and two control groups consisted of 10 chicks. 
Groups G1 and G2 had received the VAXXITEK 
HVT-IBDv vaccine subcutaneously or by intra mus-
cular route, respectively. They were also vaccinated 
with the CVI988 vaccine. Chickens in group G3, 
G4 and G5 were vaccinated at one-day of age, with 
the Cryomarex (CVI 988-Rispens+HVT) vaccine 
(Merial-Sanofi, France). No interference between 
rHVT and CVI988 has been established so far (Hein 
et al., 2011). G3 group of chicks received the inter-
mediate vaccine at 28 days of age, while G4 group 
received the intermediate plus vaccine at 26 days of 
age using the per/os method (water mixed with skim 
milk). The timing for the vaccination against IBD 
was estimated using Deventer formula based on an 
ELISA antibody titer of day old chicks, in order to 
avoid the interference with maternally derived anti-
bodies (MDA).  After seven days, groups G3 and 
G4 were vaccinated one more time against IBDv 
with the intermediate vaccines. Groups G5A and 
G5B were not vaccinated against IBDv. Group G5A 
was a challenge control, while group G5B was not 
vaccinated nor challenged during the experiment. 
Challenge with the CH/99 virus (10 birds from each 
group except G5B) was done at 48 days of age by 
oculo/nasal administration of 50µl of the crude bursal 
homogenate which was prepared as described previ-
ously (Dobrosavljević et al., 2014). Clinical symp-
toms, mortality (Le Nouen et al., 2012) and bursa/
body weight ratios (Sharma et al., 1989) were used 
to evaluate the success of the vaccinations. Bursas 
were collected from six chicks from each group sac-
rificed at 59 days of age. The number of samples for 
statistical analysis was determined according to the 
following formula, for the minimal size of the sample 
in population. 
z- Confidence level
σ - Basic standard deviation
G – The maximum permissible error
Chicks were sacrificed according to the EU 
Directive 2010/63 of the European Parliament and 
the Council on the protection of animals used for 
scientific purposes (Directive 2010/63/EU). The 
Committee of animal welfare of the Republic of 
Serbia has provided the permit (permit number 323-
07-07812/2014/05/1) for the challenge experiment. 
STATISTICAL ANALYSIS
The statistical analysis was done by using descrip-
tive statistical parameters (analysis of variance-ANO-
VA and Tukey test). The established statistical sig-
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Table 1: Clinical symptoms, mortality rate and bursa/body index in vaccinated and challenged chickens at 59 days (11 
days post challenge)
nificance was at the level of 5 and 1% and was fur-
ther elaborated using software GraphPad Prism ver-
sion 5.00 for Windows, GraphPad Software, San 
Diego, California USA, www.graphpadHYPERLINK 
“http://www.graphpad.com/”.com and MS Excel pro-
grams.
RESULTS AND DISCUSSION 
During the experiment the health status of the birds 
was recorded on a daily basis until the termination 
of the experiment. The symptoms of the acute IBDv 
(such as depression, ruffled feathers and watery diar-
rhoea) were recorded 48 hours after challenge in all 
birds from the non-vaccinated challenged group of 
chicks (group G5/A) and the mortality was 50%. In 
the groups of chicks vaccinated with the intermedi-
ate and intermediate plus vaccines (groups G3 and 
G4 respectively) the symptoms of acute IBDv were 
noticed in two chicks from each group, within two 
days from the challenge control chicks and those 
birds had succumbed to the infection. In necropsy 
discrete bleedings on pectoral muscle were seen and 
the bursa was swollen in gelatinous edema. The IBDv 
was confirmed in the bursa applying immunodiffu-
sion test. At the time of challenge,  residual MDA 
in four chicks from groups G3 and G4 respectively, 
may have still been high at 26 and 28 days of age 
and active immune responses may have been delayed 
or even absent at the time of challenge. Hence, the 
second vaccination with the intermediate vaccine did 
not provide sufficient protection for the chicks which 
was also observed in the field (Aliyu et al., 2016) 
and experimental conditions (Massi et al., 2008). 
However, in chicks that received the recombinant 
vector vaccine formulation (G1, G2) and in the con-
trol group unvaccinated and unchallenged (G5B), no 
clinical symptoms or mortality were recorded. 
Table 1
The mean bursa/body weight ratio was significantly 
higher (p<0.01) in the control non-challenged group 
and chicks that were vaccinated with the recombi-
nant vector vaccine, compared to non-vaccinated 
challenged birds and birds that received the interme-
diate and intermediate plus vaccines. Also, the mean 
bursa/body weight ratio (5.33+1.02) was significantly 
higher (p<0.05) in the control non-challenged group 
(G5/B) compared with that in the chicks vaccinated 
*number of chickens with clinical symptoms/total number of chickens in experimental group,
**Number of chickens that succumb infection/total number of chickens  in experimental group
Group Vaccinationagainst IBDV Clinical symptoms*  Mortality** 
Mean bursa
weight/g
Bursa/body 
index
G.1 vHVT13 s/c. 0/10 0/10 2.3 3.50
G 2 vHVT13 i/m. 0/10 0/10 2.85 4.12
G.3 “Intermediate” 2/10 2/10 1.0 1.55
G.4 “Intermediate plus” 2/10 2/10 0.75 1.22
G5/A Non-vaccinated/
infected 10/10 5/10 0.45 0.69
G5/B Non-vaccinated/
non-infected 0/10 0/10 3.73 5.33
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Table 2: Data on descriptive statistic analysis of the B/B weight ratio at 59 days of age (11 days post challenge) 
with the recombinant vector vaccine in group G2 
(mean B/B weight ratio of 4.12+0.55), and was sig-
nificantly higher (p<0.01) compared with that in 
the chicks vaccinated with the recombinant vec-
tor vaccine in group G1 (mean B/B weight ratio of 
3.50+0.20), while there were no significant differenc-
es between groups G2 and G1 (p>0.05). The mean 
bursa/body weight ratio in group G1 (3.50+0.20) and 
G2 (4.12+0.55) was significantly higher (p<0.01) in 
comparison with those in groups G3, G4 and G5/A.  
Table 2
The results of the challenge experiment are in 
agreement with the results obtained by Massi et al., 
2008. In their experiment, 100% protection was 
established after the subcutaneous application of 
vHVT13 in chicks that had been challenged with the 
vvIBDv. Our experiments are also in agreement with 
Darteil et al., (1995), who accomplished 100% pro-
tection against IBDv with 105  plaque forming units 
(pfu) of vaccine dose and 60% with 104 pfu vaccine 
dose per bird at one day of age, with the vHVT002 
recombinant vector vaccine. In this vaccine, the open 
reading frame of the VP2 was inserted at the deleted 
locus of the glycoprotein gene gl under the control of 
the human cytomegalovirus immediate early promot-
er. It was established that the efficacy of the vector 
vaccines depends on the potency of the promoter 
(Tsukamoto et al., 2002) as well as the proper target 
site used for insertion of the foreign gene (Darteil et 
al., 1995).
In the field situation (or in experiments with the 
commercial chicks), the titers of the maternal anti-
bodies are high at the first day of age and the inter-
ference with live-attenuated IBDv vaccine strains is 
plausible but not with the recombinant IBDv-HVT 
vaccines. The bursa of experimental birds that were 
examined 11 days post challenge showed clear dif-
ferences between the groups of chicks in our study. 
The size of the bursa and spleen was larger in the 
non-challenged and the birds vaccinated with the 
recombinant vaccine, compared to challenged control 
and groups vaccinated with the intermediate vaccines. 
Figure 1
Vaccination with live IBD vaccines is controversial 
since the occurrence of immunity depends on many 
attributes even in controlled experiments. In commer-
Different superscript letters indicates statistical significance between experimental groups of chickens: a, b, c, d, e, f, g, 
h, i, j, p<0,01; A, p<0.05, N, total number of chickens per group; x  the arithmetic average, SD, standard deviation; Sy, 
standard error; CV, coefficient of variation; X max, maximal value of the bursa/body weight ratio; X min, minimal value of 
the bursa/body weight ration. 
Groups of 
chickens
N SD Sy CV (%) X max X min
G1 6 3,50dhij 0,20 0,0982 5,61 3,75 3,27
G2 6 4,12Aefg 0,55 0,2714 13,17 4,59 3,65
G3 6 1,55ceh 0,16 0,0780 10,05 1,75 1,37
G4 6 1,22bfi 0,09 0,0460 7,54 1,35 1,15
G5/A 6 0,69agj 0,30 0,1489 43,12 1,04 0,35
G5/B 6 5,33abcdA 1,02 0,5094 19,11 6,74 4,36
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cial broilers the vaccine viruses could cause transient 
destruction of the bursa and it was postulated that a 
delay in bursa recovery influences the decrease of the 
number of target cells in the bursa which are then less 
available for the pathogenic virus (Rautenschlein et 
al., 2005). However, in experiments presented here, 2 
out of 10 birds in groups G3 and G4 had symptoms of 
acute IBD, and had succumbed to the infection
It has been established recently that even in the 
presence of high titers of maternal antibodies, the 
recombinant vaccine (vHVT13) was efficiently pro-
tecting chicks against classical, very virulent and 
variant IBDv (Bublot et al., 2007, Perozo et al., 2009, 
Prandini et al., 2016). A few experiments with the 
rHVT-IBDv have been done in commercial broilers 
and a good antibody response to IBDv was obtained 
in the research work conducted in Italy (Le Gros et 
al., 2009), Slovenia (Zorman-Rojs et al., 2011) and 
Jhenaidha (Rashid et al., 2013) after a subcutaneous 
application and when the in ovo vaccine delivery 
system was used (Roh et al., 2016). It was also shown 
that the recombinant VAXXITEK HVT-IBDv vac-
cine provided a high maternal antibody titer in proge-
ny from parents vaccinated with a single recombinant 
vaccine or if the rHVT-IBDv vaccine was combined 
with the inactivated vaccine, compared to a single 
inactivated vaccine. The protection of broiler chicks 
originating from parents vaccinated with the recom-
binant VAXXITEK HVT-IBDv which 
have been vaccinated with rHVT-IBDv 
in ovo was superior comparing to chicks 
originating from parents vaccinated with 
a single inactivated vaccine, even in the 
face of high levels of MDA (Lemiere et 
al., 2013). Authors concluded that the 
clinical protection of broilers under field 
conditions could be achieved after vac-
cination of parent flocks and their prog-
eny with the rHVT-IBDv vaccines. Gelb 
et al., (2016) has shown that the recom-
binant VAXXITEK HVT-IBDv vac-
cines offer clinical protection of broil-
er chicks with MDA against challenge 
with homologous and heterologous 
IBDv strains. These birds were protected 
based on the incidence of microscop-
ic lesions in the bursa even if interfer-
ence with the active immune response was observed. 
Active protection in specific pathogen free chicks was 
achieved at 18 DPV, onwards in their experiments. 
However, it is still not known whether the applica-
tion of the recombinant HVT-IBDv vaccine alone at 
one day of age, in the circumstances where vvIBDv 
persist on poultry farms, is sufficient for the clinical 
protection of birds. 
In situations when broilers are not routinely vacci-
nated against MDV, the HVT type of vector vaccine 
may provide some convenience for the protection 
against both diseases or to minimize the immunosup-
pression caused by both viruses (Aly et al., 2012). 
Therefore, the successes of the application of recom-
binant vaccines under field conditions and the experi-
ence gained from various epidemiological situations 
will determine the application of genetically engi-
neered vaccines for the present and future in Serbia.
In conclusion, the protective ability of the recom-
binant VAXXITEK HVT-IBDv vaccine against the 
challenge with vvIBDv (strain CH/99) was estab-
lished in this experiment. However, in the future, 
a more detailed investigation should be performed 
using virus titration, immunohistochemistry detection 
of the IBDv antigen in lymphoid organs of chicks, 
serology testing and PCR in order to gain more expe-
rience with the recombinant HVT-IBDv vaccines. 
Good management practice on poultry farms has to 
Fig 1: Bursa and spleen of chicks which have been sacrificed at 11 
days post infection with vvIBDv (CH/99 challenge strain)
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become imperative as much as vaccination, especially 
in developing countries, where vvIBDv still causes 
significant economical losses.
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